Profile: Pulmonx Corporation develops devices for the treatment of patients with chronic obstructive pulmonary disease. We offer a device designed for use in moderate to severe emphysema. We focus on developing and marketing medical devices & technologies for the diagnosis & treatment of pulmonary disorders. We are engaged in the design, development and manufacture of products that will improve the effectiveness & benefits of endoscopic lung volume reduction for patients with severe emphysema. Our Zephyr® endobronchial valve therapy involves placing small one-way valves in the lung to prevent air from entering the most diseased regions while allowing fluids and trapped air to escape. It is used to reduce the volume of the diseased portions of the lung, allowing increased ventilation to healthier areas of the lung. Chartis™ system is an assessment tool that provides precise flow and pressure readings within each lung compartment. This information enables the physician to make assessments regarding regional lung function.

FDA Registration Number: 3007797756